Carlo joins other leading authorities in drug discovery and development as part of the Biopharmaceuticals category in the Medicine Maker Power List. In his interview he reviews future trends in drug development and some of the defining moments of his…
Stopping the night time kissing bug: IRBM’s scientists recently published a Bioorganic & medicinal chemistry paper on a novel class of inhibitors for Chagas Disease, an infectious disease caused by the parasite Trypanosoma cruzi, spread by an insect commonly referred…
We were delighted to author a recent Bioanalysis Zone article discussing the power of high-resolution mass spectrometry (HRMS) when investigating peptide-based modalities in drug discovery. In the article, Simone Esposito, Research Investigator in the DMPK group, explores the extensive applications of the technology for…
Our Chief Scientific Officer, Carlo Toniatti, has been featured in The Medicine Maker, where he explored how we can catalyse the discovery and development of oncology drugs. In the article, he discusses how to overcome the challenges in developing efficacious…
9th September 2019, Pomezia, Italy - IRBM today announced the signing of a service and development agreement with The University of Texas MD Anderson Cancer Center. The agreement will focus on the development of therapeutic monoclonal antibodies against a novel…
Our Vice President of North American Business Development, Daniel Conlon, will be at the Boston BD conference on September 10. This invitation-only event brings together Biopharma thought leaders to network and explore insights into the business challenges and opportunities facing…
The latest issue of Chemistry Today features a range of interesting contributions in the field of peptide therapeutics, covering drug discovery processes as well as peptide manufacturing and efficient purification methodologies. Elisabetta Bianchi, Director of Peptide Chemistry at IRBM, was…
The essential amino acid tryptophan and the enzymes that cause its degradation influence the regulation of immune, neuronal and intestinal systems. A recent Nature Drug Discovery paper reviewed the potential of tryptophan metabolites as therapeutic targets in a range of…
Despite the fact that less than 20% of the proteome has enzymatic activity, most drug development efforts have so far focused on identifying enzymatic inhibitors. However, targeting a cell’s proteasomal machinery is now considered an effective area of research. As…
IRBM researchers, led by Dr. Edith Monteagudo, have published a novel method to assess metabolism at the injection site of subcutaneously administered therapeutic peptides. Click on the link below to visit the article’s page on ScienceDirect. A liquid chromatography high-resolution…
